DS
STIM icon

David Shaw’s Neuronetics STIM Stock Holding History

David Shaw’s Portfolio STIM Stock Details STIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-31,628
Closed -$86.3K – 4992
2025
Q3 		$86.3K Buy
+31,628
New +$112K ﹤0.01% 4365
2022
Q2 		– Sell
-48,161
Closed -$146K – 5757
2022
Q1 		$146K Buy
+48,161
New +$163K ﹤0.01% 4941
2021
Q3 		– Sell
-16,366
Closed -$262K – 5217
2021
Q2 		$262K Buy
+16,366
New +$226K ﹤0.01% 4338

Other funds holding STIM

MAM
Madryn Asset Management New York $36.9M AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LG
Lane Generational Dover, Massachusetts $114M AUM 43.8% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
FCM
FourWorld Capital Management New York $110M AUM 44.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

David Shaw's STIM Position: Q4 2025 in Review

David Shaw sold out of Neuronetics (STIM) in Q4 2025, closing a stake of 31,628 shares — an estimated $86.3K sold.

David Shaw first reported a position in STIM in Q2 2021 and held it in 3 quarters. The position peaked at $262K in Q2 2021. 95 funds tracked by Wall St. Rank hold STIM as of Q4 2025.

  • David Shaw reported no remaining Neuronetics position as of Q4 2025 after selling out during the quarter.
  • David Shaw sold 31,628 Neuronetics shares in Q4 2025, an estimated $86.3K.
  • David Shaw first reported a position in Neuronetics in Q2 2021 and held it in 3 quarters.
  • David Shaw's Neuronetics position peaked at $262K in Q2 2021.
  • 95 funds tracked by Wall St. Rank held Neuronetics as of Q4 2025.

Based on D.E. Shaw & Co's 13F filing for Q4 2025, filed 17 Feb 2026.